 Connection
Michael Kahn to Leukemia, Myelogenous, Chronic, BCR-ABL Positive
This is a "connection" page, showing publications Michael Kahn has written about Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.397 |
|
|
|
-
Chimge NO, Chen MH, Nguyen C, Zhao Y, Wu X, Gonzalez PG, Ogana H, Hurwitz S, Teo JL, Chen X, Du J, Jin V, Kim YM, Ono M, Argüello RJ, Kahn M. A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I. Curr Mol Pharmacol. 2024; 17:e060923220758.
Score: 0.769
-
Zhao Y, Wu K, Wu Y, Melendez E, Smbatyan G, Massiello D, Kahn M. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol. 2018; 11(2):113-121.
Score: 0.507
-
Kim YM, Gang EJ, Kahn M. CBP/Catenin antagonists: Targeting LSCs' Achilles heel. Exp Hematol. 2017 08; 52:1-11.
Score: 0.121
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|